131 related articles for article (PubMed ID: 32750565)
1. Corrigendum to "Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview" [Eur. J. Med. Chem. 194 (2020) 112260].
Mondal S; Adhikari N; Banerjee S; Amin SA; Jha T
Eur J Med Chem; 2020 Nov; 205():112642. PubMed ID: 32750565
[No Abstract] [Full Text] [Related]
2. Corrigendum to"Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo"[Eur. J. Med. Chem. 190 (2020 Mar 15) 112086].
Ojha R; Nepali K; Chen CH; Chuang KH; Wu TY; Lin TE; Hsu KC; Chao MW; Lai MJ; Lin MH; Huang HL; Chang CD; Pan SL; Chen MC; Liou JP
Eur J Med Chem; 2020 Sep; 201():112404. PubMed ID: 32526554
[No Abstract] [Full Text] [Related]
3. Corrigendum to "Optimization of physicochemical properties for 4-Anilinoquinazoline inhibitors of trypanosome proliferation" [Eur. J. Med. Chem. 141 (2017) 446-459].
Woodring JL; Bachovchin KA; Brady KG; Gallerstein MF; Erath J; Tanghe S; Leed SE; Rodriguez A; Mensa-Wilmot K; Sciotti RJ; Pollastri MP
Eur J Med Chem; 2018 May; 152():515. PubMed ID: 29754075
[No Abstract] [Full Text] [Related]
4. Corrigendum to "Pyridine and nitro-phenyl linked 1,3,4-thiadiazoles as MDR-TB inhibitors" [Eur. J. Med. Chem. 167 (2019) 1-9].
Patel H; Jadhav H; Ansari I; Pawara R; Surana S
Eur J Med Chem; 2020 Aug; 200():112413. PubMed ID: 32512481
[No Abstract] [Full Text] [Related]
5. Corrigendum to "Design, synthesis and anticancer properties of isocombretapyridines as potent colchicine binding site inhibitors" [Eur. J. Med. Chem. 197 (2020) 112308].
Shuai W; Li X; Li W; Xu F; Lu L; Yao H; Yang L; Zhu H; Xu S; Zhu Z; Xu J
Eur J Med Chem; 2020 Aug; 200():112464. PubMed ID: 32512484
[No Abstract] [Full Text] [Related]
6. Corrigendum to "From irreversible to reversible covalent inhibitors: Harnessing the andrographolide scaffold for anti-inflammatory action" [Eur. J. Med. Chem. 204 (2020) 112481].
Tran QTN; Tan DWS; Wong WSF; Chai CLL
Eur J Med Chem; 2021 Jan; 209():112943. PubMed ID: 33097302
[No Abstract] [Full Text] [Related]
7. Corrigendum to: Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib [Eur. J. Med. Chem. 172 (2019) 143-153].
Poratti M; Marzaro G
Eur J Med Chem; 2020 Jun; 195():112272. PubMed ID: 32251743
[No Abstract] [Full Text] [Related]
8. Corrigendum to "Design, synthesis, and biological evaluation of a new class of histone acetyltransferase p300 inhibitors" [Eur. J. Med. Chem. 180 (2019) 171e190].
Liu R; Zhang Z; Yang H; Zhou K; Geng M; Zhou W; Zhang M; Huang X; Li Y
Eur J Med Chem; 2020 Jan; 186():111899. PubMed ID: 31787358
[No Abstract] [Full Text] [Related]
9. Corrigendum to "1,4-Naphthoquinones as inhibitors of Itch, a HECT domain-E3 ligase, and tumor growth suppressors in multiple myeloma" [Eur. J. Med. Chem. 140 (2017) 84-91].
Liu YM; HuangFu WC; Huang HL; Wu WC; Chen YL; Yen Y; Huang HL; Nien CY; Lai MJ; Pan SL; Liou JP
Eur J Med Chem; 2020 Sep; 202():112633. PubMed ID: 32688164
[No Abstract] [Full Text] [Related]
10. Corrigendum to <' Omipalisib inspired macrocycles as dual PI3K/mTOR inhibitors' [Eur. J. Med. Chem. 211 (2021), 113109].
Alvarez RM; García AB; Riesco-Fagundo C; Martín JI; Varela C; Rodríguez Hergueta A; González Cantalapiedra E; Oyarzabal J; Di Geronimo B; Lorenzo M; Albarrán MI; Cebriá A; Cebrián D; Martínez-González S; Blanco-Aparicio C; Pastor J
Eur J Med Chem; 2021 Nov; 224():113703. PubMed ID: 34284231
[No Abstract] [Full Text] [Related]
11. Corrigendum to "Design and synthesis of highly TRAIL expression HDAC inhibitors based on ONC201 to promote apoptosis of colorectal cancer" [Eur. J. Med. Chem. 238 (2022) 1-20/114484].
Cui H; Hu Z; Yang K; Huang J; Wu Y; Chen Q; Wei R; Wang P; Wang H; Li H; Chen Y; Lu T; Yao Y; Zhu Y
Eur J Med Chem; 2022 Oct; 240():114568. PubMed ID: 35809536
[No Abstract] [Full Text] [Related]
12. Corrigendum to "Design, synthesis, and biological evaluation of 1,6-naphthyridine-2-one derivatives as novel FGFR4 inhibitors for the treatment of colorectal cancer" [Eur. J. Med. Chem. 259 (2023) 115703/5].
Fang B; Lai Y; Yan H; Ma Y; Ni Z; Zhu Q; Zhang J; Ye Y; Wang M; Wang P; Wang Y; Zhang S; Hui M; Wang D; Zhao Y; Li X; Wang K; Liu Z
Eur J Med Chem; 2024 Mar; 268():116230. PubMed ID: 38368135
[No Abstract] [Full Text] [Related]
13. Corrigendum to "Design, synthesis and evaluation of novel thienopyrimidine-based agents bearing diaryl urea functionality as potential inhibitors of angiogenesis" [Eur. J. Med. Chem 209 (2021) 112942].
Faraji A; Oghabi Bakhshaiesh T; Hasanvand Z; Motahari R; Nazeri E; Boshagh MA; Firoozpour L; Mehrabi H; Khalaj A; Esmaeili R; Foroumadi A
Eur J Med Chem; 2021 Mar; 214():113228. PubMed ID: 33550180
[No Abstract] [Full Text] [Related]
14. Corrigendum to "N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression"[Eur. J. Med. Chem. 2020 Jan 1;185:111725].
Mehndiratta S; Lin MH; Wu YW; Chen CH; Wu TY; Chuang KH; Chao MW; Chen YY; Pan SL; Chen MC; Liou JP
Eur J Med Chem; 2020 Aug; 199():112406. PubMed ID: 32408215
[No Abstract] [Full Text] [Related]
15. Corrigendum to "Synthesis and evaluation of 2,5-furan, 2,5-thiophene and 3,4-thiophene-based derivatives as CXCR4 inhibitors" [Eur. J. Med. Chem. 181 (2019) 111562].
Gaines T; Garcia F; Virani S; Liang Z; Yoon Y; Oum YH; Shim H; Mooring SR
Eur J Med Chem; 2023 Dec; 261():115753. PubMed ID: 37634992
[No Abstract] [Full Text] [Related]
16. Corrigendum to <'Synthesis and biological evaluation of 2,6-disubstituted-9H-purine, 2,4-disubstitued-thieno[3,2-d]pyrimidine and -7H-pyrrolo[2,3-d] pyrimidine analogues as novel CHK1 inhibitors' [Eur. J. Med. Chem. 151 (2018) 836-848].
Tian C; Han Z; Li Y; Wang M; Yang J; Wang X; Zhang Z; Liu J
Eur J Med Chem; 2019 Jul; 173():184. PubMed ID: 31003059
[No Abstract] [Full Text] [Related]
17. Corrigendum to "Discovery of novel nonsteroidal VDR agonists with novel diarylmethane skeleton for the treatment of breast cancer" [Eur. J. Med. Chem. 163 (2019) 787-803].
Wang C; Wang B; Hou S; Xue L; Kang Z; Du J; Li Y; Liu X; Wang Q; Zhang C
Eur J Med Chem; 2020 Jan; 186():111907. PubMed ID: 31791642
[No Abstract] [Full Text] [Related]
18. Corrigendum to "Tetrahydropyridin-4-ylpicolinoylglycines as novel and orally active prolyl hydroxylase 2 (PHD2) inhibitors for the treatment of renal anemia" [Eur. J. Med. Chem. 238 (2022) 114479].
Su K; Li Z; Zhang L; Fang S; Mao M; Sun Z; Zhang X
Eur J Med Chem; 2023 Nov; 259():115692. PubMed ID: 37550158
[No Abstract] [Full Text] [Related]
19. Corrigendum to "Design and synthesis of novel artemisinin hybrids with potent activities against human colorectal cancer cells in vitro and in vivo" [Eur. J. Med. Chem. 182 (2019) 111665].
Wang LL; Kong L; Liu H; Zhang Y; Zhang L; Liu X; Yuan F; Li Y; Zuo Z
Eur J Med Chem; 2020 May; 194():112256. PubMed ID: 32220686
[No Abstract] [Full Text] [Related]
20. Corrigendum to "Synthesis and cytotoxic activity of novel A-ring cleaved ursolic acid derivatives in human non-small cell lung cancer cells" [Eur. J. Med. Chem. 123 (2016) 317-331].
Mendes VIS; Bartholomeusz GA; Ayres M; Gandhi V; Salvador JAR
Eur J Med Chem; 2016 Nov; 124():1004-1005. PubMed ID: 27783971
[No Abstract] [Full Text] [Related]
[Next] [New Search]